已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

利拉鲁肽 医学 脂肪性肝炎 安慰剂 内科学 脂肪肝 临床试验 胃肠病学 糖尿病 脂肪变性 2型糖尿病 外科 疾病 内分泌学 病理 替代医学
作者
Matthew James Armstrong,Piers Gaunt,Guruprasad Padur Aithal,Darren Barton,Diana Hull,Richard Parker,Jonathan Hazlehurst,Kathy Guo,George F. Abouda,Mark A. Aldersley,Deborah D. Stocken,Stephen C. L. Gough,Jeremy Tomlinson,Rachel Mary Brown,Stefan G. Hübscher,Philip Noel Newsome
出处
期刊:The Lancet [Elsevier BV]
卷期号:387 (10019): 679-690 被引量:2194
标识
DOI:10.1016/s0140-6736(15)00803-x
摘要

Summary

Background

Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic steatosis, concentrations of liver enzymes, and insulin resistance in murine models of fatty liver disease. These analogues are licensed for type 2 diabetes, but their efficacy in patients with non-alcoholic steatohepatitis is unknown. We assessed the safety and efficacy of the long-acting GLP-1 analogue, liraglutide, in patients with non-alcoholic steatohepatitis.

Methods

This multicentre, double-blinded, randomised, placebo-controlled phase 2 trial was conducted in four UK medical centres to assess subcutaneous injections of liraglutide (1·8 mg daily) compared with placebo for patients who are overweight and show clinical evidence of non-alcoholic steatohepatitis. Patients were randomly assigned (1:1) using a computer-generated, centrally administered procedure, stratified by trial centre and diabetes status. The trial was designed using A'Hern's single-group method, which required eight (38%) of 21 successes in the liraglutide group for the effect of liraglutide to be considered clinically significant. Patients, investigators, clinical trial site staff, and pathologists were masked to treatment assignment throughout the study. The primary outcome measure was resolution of definite non-alcoholic steatohepatitis with no worsening in fibrosis from baseline to end of treatment (48 weeks), as assessed centrally by two independent pathologists. Analysis was done by intention-to-treat analysis, which included all patients who underwent end-of-treatment biopsy. The trial was registered with ClinicalTrials.gov, number NCT01237119.

Findings

Between Aug 1, 2010, and May 31, 2013, 26 patients were randomly assigned to receive liraglutide and 26 to placebo. Nine (39%) of 23 patients who received liraglutide and underwent end-of-treatment liver biopsy had resolution of definite non-alcoholic steatohepatitis compared with two (9%) of 22 such patients in the placebo group (relative risk 4·3 [95% CI 1·0–17·7]; p=0·019). Two (9%) of 23 patients in the liraglutide group versus eight (36%) of 22 patients in the placebo group had progression of fibrosis (0·2 [0·1–1·0]; p=0·04). Most adverse events were grade 1 (mild) to grade 2 (moderate) in severity, transient, and similar in the two treatment groups for all organ classes and symptoms, with the exception of gastrointestinal disorders in 21 (81%) of 23 patients in the liraglutide group and 17 (65%) of 22 patients in the placebo group, which included diarrhoea (ten [38%] patients in the liraglutide group vs five [19%] in the placebo group), constipation (seven [27%] vs none), and loss of appetite (eight [31%] vs two [8%]).

Interpretation

Liraglutide was safe, well tolerated, and led to histological resolution of non-alcoholic steatohepatitis, warranting extensive, longer-term studies.

Funding

Wellcome Trust, National Institute of Health Research, and Novo Nordisk.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Akim的应助被wmy采纳,获得10
1秒前
two发布了新的文献求助20
2秒前
2秒前
3秒前
3秒前
4秒前
余悲也白发布了新的文献求助10
6秒前
慕青的应助被潘健康采纳,获得10
7秒前
7秒前
橘子味棒冰完成签到,获得积分10
7秒前
秋风的应助被温暖砖头采纳,获得20
8秒前
tjzbw发布了新的文献求助10
9秒前
9秒前
aa发布了新的文献求助10
9秒前
无极微光的应助被SZL2026采纳,获得20
10秒前
12秒前
3921337477发布了新的文献求助10
12秒前
雪白菠萝关注了科研通微信公众号
12秒前
万能图书馆的应助被kjh采纳,获得10
12秒前
111完成签到,获得积分10
12秒前
wmy发布了新的文献求助10
13秒前
13秒前
14秒前
14秒前
tttt发布了新的文献求助30
14秒前
15秒前
菜菜发布了新的文献求助30
15秒前
852的应助被不糊不喝生椰汁采纳,获得10
15秒前
潘健康完成签到,获得积分10
17秒前
18秒前
核桃发布了新的文献求助10
18秒前
李爱国的应助被wmy采纳,获得10
19秒前
19秒前
潘健康发布了新的文献求助10
20秒前
21秒前
11号yan完成签到 ,获得积分10
21秒前
22秒前
lmd发布了新的文献求助10
22秒前
OHDJSZMS完成签到,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184536
求助须知:如何正确求助?哪些是违规求助? 9573526
关于积分的说明 21832132
捐赠科研通 7781791
什么是DOI,文献DOI怎么找? 3434376
关于科研通互助平台的介绍 2558490
邀请新用户注册赠送积分活动 2480989